Chemotherapy as adjuvant therapy for completely resected non-small-cell lung cancer: have we made progress?
R Feld
JCO Apr 1 1996: 1045–1047. [PDF]
	Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery
	H Wada, S Hitomi, and T Teramatsu
	JCO Apr 1 1996: 1048–1054. [Abstract] [PDF]
	Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: radiation therapy oncology group protocol 91-06
	JS Lee, C Scott, R Komaki, FV Fossella, GS Dundas, S McDonald, RW Byhardt, and WJ Curran, Jr
	JCO Apr 1 1996: 1055–1064. [Abstract] [PDF]
	Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study
	B Jeremic, Y Shibamoto, L Acimovic, and S Milisavljevic
	JCO Apr 1 1996: 1065–1070. [Abstract] [PDF]
	Severe lymphocytopenia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer
	B Reckzeh, H Merte, KH Pfluger, R Pfab, M Wolf, and K Havemann
	JCO Apr 1 1996: 1071–1076. [Abstract] [PDF]
	Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo- controlled multicenter study
	JP Simons, NK Aaronson, JF Vansteenkiste, GP ten Velde, MJ Muller, BM Drenth, FL Erdkamp, EG Cobben, EJ Schoon, JB Smeets, HC Schouten, M Demedts, HF Hillen, GH Blijham, and EF Wouters
	JCO Apr 1 1996: 1077–1084. [Abstract] [PDF]
	Linear accelerator-based stereotaxic radiosurgery for brain metastases:the influence of number of lesions on survival
	J Joseph, JR Adler, RS Cox, and SL Hancock
	JCO Apr 1 1996: 1085–1092. [Abstract] [PDF]
	Patterns-of-failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: the need for improved systemic and locoregional treatment
	GE Hanks, AL Hanlon, G Hudes, WR Lee, W Suasin, and TE Schultheiss
	JCO Apr 1 1996: 1093–1097. [Abstract] [PDF]
	High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: treatment results and prognostic factors for survival and toxicity
	RJ Motzer, M Mazumdar, GJ Bosl, DF Bajorin, A Amsterdam, and V Vlamis
	JCO Apr 1 1996: 1098–1105. [Abstract] [PDF]
	Short-course adjuvant chemotherapy in high-risk stage I nonseminomatous germ cell tumors of the testis: a Medical Research Council report
	MH Cullen, SP Stenning, MC Parkinson, SD Fossa, SB Kaye, AH Horwich, SJ Harland, MV Williams, and R Jakes
	JCO Apr 1 1996: 1106–1113. [Abstract] [PDF]
	Impact of preleukapheresis cell counts on collection results and correlation of progenitor-cell dose with engraftment after high-dose chemotherapy in patients with germ cell cancer
	N Schwella, J Beyer, I Schwaner, HG Heuft, O Rick, D Huhn, S Serke, and W Siegert
	JCO Apr 1 1996: 1114–1121. [Abstract] [PDF]
	Expression of a CD44 variant containing exons 8 to 10 is a useful independent factor for the prediction of prognosis in colorectal cancer patients
	A Yamaguchi, T Urano, T Goi, M Saito, K Takeuchi, K Hirose, G Nakagawara, H Shiku, and K Furukawa
	JCO Apr 1 1996: 1122–1127. [Abstract] [PDF]
	Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
	ML Rothenberg, JR Eckardt, JG Kuhn, HA Burris, 3rd, J Nelson, SG Hilsenbeck, GI Rodriguez, AM Thurman, LS Smith, SG Eckhardt, GR Weiss, GL Elfring, DA Rinaldi, LJ Schaaf, and DD Von Hoff
	JCO Apr 1 1996: 1128–1135. [Abstract] [PDF]
	Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration
	JL Misset, M di Palma, M Delgado, R Plagne, P Chollet, P Fumoleau, B Le Mevel, D Belpomme, J Guerrin, P Fargeot, R Metz, M Ithzaki, C Hill, and G Mathe
	JCO Apr 1 1996: 1136–1145. [Abstract] [PDF]
	Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group
	L Bastholt, M Dalmark, SB Gjedde, P Pfeiffer, D Pedersen, E Sandberg, M Kjaer, HT Mouridsen, C Rose, OS Nielsen, P Jakobsen, and SM Bentzen
	JCO Apr 1 1996: 1146–1155. [Abstract] [PDF]
	Minimal toxicity and mortality in high-risk breast cancer patients receiving high-dose cyclophosphamide, thiotepa, and carboplatin plus autologous marrow/stem-cell transplantation and comprehensive supportive care
	HK Holland, SP Dix, RB Geller, SM Devine, LT Heffner, DG Connaghan, CD Hillyer, LL Hughes, RL Miller, MR Moore, EF Winton, and JR Wingard
	JCO Apr 1 1996: 1156–1164. [Abstract] [PDF]
	Lonidamine significantly increases the activity of epirubicin in patients with advanced breast cancer: results from a multicenter prospective randomized trial
	L Dogliotti, A Berruti, T Buniva, P Zola, MG Bau, A Farris, MG Sarobba, A Bottini, P Alquati, F Deltetto, P Gosso, C Monzeglio, G Moro, M Sussio, and D Perroni
	JCO Apr 1 1996: 1165–1172. [Abstract] [PDF]
	Phase I crossover study of paclitaxel with r-verapamil in patients with metastatic breast cancer
	AW Tolcher, KH Cowan, D Solomon, F Ognibene, B Goldspiel, R Chang, MH Noone, AM Denicoff, CS Barnes, MR Gossard, PA Fetsch, SL Berg, FM Balis, DJ Venzon, and JA O'Shaughnessy
	JCO Apr 1 1996: 1173–1184. [Abstract] [PDF]
	Phase I/II trial of biweekly paclitaxel and cisplatin in the treatment of metastatic breast cancer
	KA Gelmon, SE O'Reilly, AW Tolcher, C Campbell, C Bryce, J Ragaz, C Coppin, IH Plenderleith, D Ayers, B McDermott, L Nakashima, D Healey, and N Onetto
	JCO Apr 1 1996: 1185–1191. [Abstract] [PDF]
	Intensive concomitant chemoradiotherapy in locally advanced unresectable squamous cell carcinoma of the head and neck: a phase II study of radiotherapy with cisplatin and 7-week continuous infusional fluorouracil
	P Wibault, MA Bensmaine, M de Forni, JP Armand, E Tellez Bernal, T Guillot, G Recondo, C Domenge, F Janot, C Borel, B Luboinski, F Eschwege, and E Cvitkovic
	JCO Apr 1 1996: 1192–1200. [Abstract] [PDF]
	Synovial sarcoma: prognostic significance of tumor size, margin of resection, and mitotic activity for survival
	S Singer, EH Baldini, GD Demetri, JA Fletcher, and JM Corson
	JCO Apr 1 1996: 1201–1208. [Abstract] [PDF]
	Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen
	M Juweid, RM Sharkey, T Behr, LC Swayne, AD Rubin, T Herskovic, D Hanley, A Markowitz, R Dunn, J Siegel, T Kamal, and DM Goldenberg
	JCO Apr 1 1996: 1209–1217. [Abstract] [PDF]
	Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions
	R Corona, A Mele, M Amini, G De Rosa, G Coppola, P Piccardi, M Fucci, P Pasquini, and T Faraggiana
	JCO Apr 1 1996: 1218–1223. [Abstract] [PDF]
	Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors
	EK Rowinsky, LB Grochow, SE Sartorius, MK Bowling, SH Kaufmann, D Peereboom, and RC Donehower
	JCO Apr 1 1996: 1224–1235. [Abstract] [PDF]
	Phase I and pharmacologic study of 9-aminocamptothecin given by 72-hour infusion in adult cancer patients
	W Dahut, N Harold, C Takimoto, C Allegra, A Chen, JM Hamilton, S Arbuck, M Sorensen, F Grollman, H Nakashima, R Lieberman, M Liang, W Corse, and J Grem
	JCO Apr 1 1996: 1236–1244. [Abstract] [PDF]
	Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?
	A Zoubek, B Dockhorn-Dworniczak, O Delattre, H Christiansen, F Niggli, I Gatterer-Menz, TL Smith, H Jurgens, H Gadner, and H Kovar
	JCO Apr 1 1996: 1245–1251. [Abstract] [PDF]
	Improved survival for children with B-cell acute lymphoblastic leukemia and stage IV small noncleaved-cell lymphoma: a pediatric oncology group study
	WP Bowman, JJ Shuster, B Cook, T Griffin, F Behm, J Pullen, M Link, D Head, A Carroll, C Berard, and S Murphy
	JCO Apr 1 1996: 1252–1261. [Abstract] [PDF]
	Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma
	P McLaughlin, FB Hagemeister, JE Romaguera, AH Sarris, O Pate, A Younes, F Swan, M Keating, and F Cabanillas
	JCO Apr 1 1996: 1262–1268. [Abstract] [PDF]
	Mantle-cell lymphoma: a population-based clinical study
	GA Velders, JC Kluin-Nelemans, CJ De Boer, J Hermans, EM Noordijk, E Schuuring, MH Kramer, WA Van Deijk, JB Rahder, PM Kluin, and JH Van Krieken
	JCO Apr 1 1996: 1269–1274. [Abstract] [PDF]
	Phase I trial of dose escalation with growth factor support in patients with previously untreated diffuse aggressive lymphomas: determination of the maximum-tolerated dose of ProMACE-CytaBOM
	LI Gordon, J Anderson, TM Habermann, JN Winter, J Glick, RJ Schilder, and P Cassileth
	JCO Apr 1 1996: 1275–1281. [Abstract] [PDF]
	Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University
	MP Mac Manus and RT Hoppe
	JCO Apr 1 1996: 1282–1290. [Abstract] [PDF]
	Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation
	N Milpied, AK Fielding, RM Pearce, P Ernst, and AH Goldstone
	JCO Apr 1 1996: 1291–1296. [Abstract] [PDF]
	Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease
	A Hirsch, N Vander Els, DJ Straus, EG Gomez, D Leung, CS Portlock, and J Yahalom
	JCO Apr 1 1996: 1297–1305. [Abstract] [PDF]
	Autologous peripheral-blood progenitor-cell support following high- dosechemotherapy or chemoradiotherapy in patients with high-risk multiple myeloma
	G Marit, C Faberes, JL Pico, JM Boiron, JH Bourhis, P Brault, P Bernard, C Foures, P Cony-Makhoul, M Puntous, G Vezon, A Broustet, D Girault, and J Reiffers
	JCO Apr 1 1996: 1306–1313. [Abstract] [PDF]
	Allogeneic blood cell transplantation without posttransplant colony- stimulating factors in patients with hematopoietic neoplasm: a phase II study
	C Rosenfeld, R Collins, L Pineiro, E Agura, and J Nemunaitis
	JCO Apr 1 1996: 1314–1319. [Abstract] [PDF]
	Phase I trial of an antisense oligonucleotide OL(1)p53 in hematologic malignancies
	MR Bishop, PL Iversen, E Bayever, JG Sharp, TC Greiner, BL Copple, R Ruddon, G Zon, J Spinolo, M Arneson, JO Armitage, and A Kessinger
	JCO Apr 1 1996: 1320–1326. [Abstract] [PDF]
	Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant
	CB Miller, S Piantadosi, GB Vogelsang, DC Marcellus, L Grochow, MJ Kennedy, and RJ Jones
	JCO Apr 1 1996: 1327–1332. [Abstract] [PDF]
	BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases
	G Dolken, G Illerhaus, C Hirt, and R Mertelsmann
	JCO Apr 1 1996: 1333–1344. [Abstract] [PDF]
	Therapy of untreated acute myeloid leukemia in the elderly: remission- induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide
	EJ Bow, JA Sutherland, MG Kilpatrick, GJ Williams, JJ Clinch, TB Shore, M Rubinger, and BA Schacter
	JCO Apr 1 1996: 1345–1352. [Abstract] [PDF]
	Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation
	J Sierra, S Brunet, A Granena, T Olive, J Bueno, JM Ribera, J Petit, C Besses, A Llorente, R Guardia, J Macia, M Rovira, I Badell, E Vela, C Diaz de Heredia, P Vivancos, E Carreras, E Feliu, E Montserrat, A Julia, J Cubells, C Rozman, A Domingo, and JJ Ortega
	JCO Apr 1 1996: 1353–1363. [Abstract] [PDF]
	Reducing patient eligibility criteria in cancer clinical trials
	SL George
	JCO Apr 1 1996: 1364–1370. [Abstract] [PDF]
	Use of cytokines in the treatment of acute myelocytic leukemia: a critical review
	RB Geller
	JCO Apr 1 1996: 1371–1382. [Abstract] [PDF]
	Radioimmunotherapy: recent results and future directions
	RB Wilder, GL DeNardo, and SJ DeNardo
	JCO Apr 1 1996: 1383–1400. [Abstract] [PDF]
Is oral ondansetron really efficacious in the control of cisplatin- induced delayed emesis?
M Martin
JCO Apr 1 1996: 1401–1402. [PDF]
Combined modality therapy of lung cancer and lung tolerance
RP Abratt
JCO Apr 1 1996: 1402–1403. [PDF]
Paclitaxel and doxorubicin in metastatic breast cancer
S Sharma
JCO Apr 1 1996: 1403a. [PDF]
Breast cancer: systemic benefit of locoregional treatment
G Lawrence, P Castro, and B Collins
JCO Apr 1 1996: 1403b–1404. [PDF]
Acute myeloid leukemia-type chemotherapy for myelodysplasia
P Anderlini, S Pierce, H Kantarjian, and E Estey
JCO Apr 1 1996: 1404–1405. [PDF]
Interleukin-10 and phenomena of tolerance in interleukin-2 therapy
M Engelhardt, U Brennscheidt, R Mertelsmann, and A Lindemann
JCO Apr 1 1996: 1405–1406. [PDF]
Cessation of follow-up tests with limited utility: a patient's perspective
CL Loprinzi
JCO Apr 1 1996: 1406a. [PDF]
To test or not to test: where is the truth?
M Gilseth
JCO Apr 1 1996: 1406b–1407. [PDF]

To see an article, click its [Full Text] or [PDF] link. To review many abstracts, check the boxes to the left of the titles you want, and click the 'Get All Checked Abstract(s)' button. To see one abstract at a time, click its [Abstract] link.